RHHBY
Roche Holdings AG ADR

3,642
Mkt Cap
$288.8B
Volume
687,526.00
52W High
$60.85
52W Low
$37.51
PE Ratio
21.62
RHHBY Fundamentals
Price
$52.40
Prev Close
$52.36
Open
$52.84
50D MA
$50.65
Beta
0.38
Avg. Volume
2.17M
EPS (Annual)
$2.44
P/B
7.82
Rev/Employee
$656,820.44
$358,793.41
Loading...
Loading...
News
all
press releases
Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?
Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.
Zacks
News Placeholder
More News
News Placeholder
How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026
ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.
Zacks
News Placeholder
AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors
AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.
Zacks
News Placeholder
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
Zacks
News Placeholder
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
Zacks
News Placeholder
AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings
AstraZeneca and Daiichi win FDA approval for Enhertu in two new HER2-positive early breast cancer treatment settings.
Zacks
News Placeholder
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer
RHHBY wins FDA approval for Tecentriq label expansion as a ctDNA-guided adjuvant therapy for bladder cancer patients at high risk of recurrence.
Zacks
News Placeholder
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?
Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.
Zacks
News Placeholder
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up
ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.
Zacks
News Placeholder
Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?
Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.
Zacks
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available